Emerging Role of Circulating Tumor Cells in Immunotherapy

Overview

Journal Theranostics

Date 2021 Aug 2

PMID 34335980

Citations 14

Authors

Alexey Rzhevskiy

Alina Kapitannikova

Polina Malinina

Arthur Volovetsky

Hamidreza Aboulkheyr Es

Arutha Kulasinghe

Jean Paul Thiery

Anna Maslennikova

Andrei V Zvyagin

Majid Ebrahimi Warkiani

Affiliations

Soon will be listed here.

Abstract

Over the last few years, immunotherapy, in particular, immune checkpoint inhibitor therapy, has revolutionized the treatment of several types of cancer. At the same time, the uptake in clinical oncology has been slow owing to the high cost of treatment, associated toxicity profiles and variability of the response to treatment between patients. In response, personalized approaches based on predictive biomarkers have emerged as new tools for patient stratification to achieve effective immunotherapy. Recently, the enumeration and molecular analysis of circulating tumor cells (CTCs) have been highlighted as prognostic biomarkers for the management of cancer patients during chemotherapy and for targeted therapy in a personalized manner. The expression of immune checkpoints on CTCs has been reported in a number of solid tumor types and has provided new insight into cancer immunotherapy management. In this review, we discuss recent advances in the identification of immune checkpoints using CTCs and shed light on the potential applications of CTCs towards the identification of predictive biomarkers for immunotherapy.

Citing Articles

Focused shock waves and inertial cavitation release tumor-associated antigens from renal cell carcinoma.

Hosano N, Moosavi-Nejad Z, Hide T, Hosano H Ultrason Sonochem. 2024; 111:107078.

PMID: 39327122 PMC: 11600062. DOI: 10.1016/j.ultsonch.2024.107078.

Liquid biopsy: paving a new avenue for cancer research.

Kurma K, Eslami-S Z, Alix-Panabieres C, Cayrefourcq L Cell Adh Migr. 2024; 18(1):1-26.

PMID: 39219215 PMC: 11370957. DOI: 10.1080/19336918.2024.2395807.

Palladium-103 (Pd/Rh), a promising Auger-electron emitter for targeted radionuclide therapy of disseminated tumor cells - absorbed doses in single cells and clusters, with comparison to Lu and Tb.

Hindie E, Larouze A, Alcocer-Avila M, Morgat C, Champion C Theranostics. 2024; 14(11):4318-4330.

PMID: 39113794 PMC: 11303077. DOI: 10.7150/thno.95436.

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.

Kotsifaki A, Maroulaki S, Armakolas A Int J Mol Sci. 2024; 25(9).

PMID: 38732051 PMC: 11084220. DOI: 10.3390/ijms25094832.

Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.

Wiegmans A, Ivanova E, Naei V, Monkman J, Fletcher J, Mullally W Clin Exp Metastasis. 2024; 41(3):219-228.

PMID: 38416302 PMC: 11213738. DOI: 10.1007/s10585-024-10270-w.

References

Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View

Luen S, Savas P, Fox S, Salgado R, Loi S . Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017; 49(2):141-155. DOI: 10.1016/j.pathol.2016.10.010. View

Horn L, Spigel D, Vokes E, Holgado E, Ready N, Steins M . Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933. PMC: 6075826. DOI: 10.1200/JCO.2017.74.3062. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Earhart C, Hughes C, Gaster R, Ooi C, Wilson R, Zhou L . Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab Chip. 2013; 14(1):78-88. PMC: 4144998. DOI: 10.1039/c3lc50580d. View

Cheng B, Tong G, Wu X, Cai W, Li Z, Tong Z . Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer. Onco Targets Ther. 2019; 12:7887-7896. PMC: 6768312. DOI: 10.2147/OTT.S223222. View

Hong X, Sullivan R, Kalinich M, Kwan T, Giobbie-Hurder A, Pan S . Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018; 115(10):2467-2472. PMC: 5877960. DOI: 10.1073/pnas.1719264115. View

10.

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

11.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

12.

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

13.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S . Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22):6980-6. DOI: 10.1158/1078-0432.CCR-09-1095. View

14.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

15.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

16.

Malhotra J, Jabbour S, Aisner J . Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017; 6(2):196-211. PMC: 5420529. DOI: 10.21037/tlcr.2017.03.01. View

17.

Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou E . SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2012; 59(1):270-9. DOI: 10.1373/clinchem.2012.191551. View

18.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

19.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

20.

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali H . Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6(7):5449-64. PMC: 4467160. DOI: 10.18632/oncotarget.3216. View